AGL 39.18 Decreased By ▼ -0.82 (-2.05%)
AIRLINK 127.57 Decreased By ▼ -1.49 (-1.15%)
BOP 6.85 Increased By ▲ 0.10 (1.48%)
CNERGY 4.67 Increased By ▲ 0.18 (4.01%)
DCL 8.50 Decreased By ▼ -0.05 (-0.58%)
DFML 41.15 Increased By ▲ 0.33 (0.81%)
DGKC 82.25 Increased By ▲ 1.29 (1.59%)
FCCL 33.00 Increased By ▲ 0.23 (0.7%)
FFBL 74.24 Decreased By ▼ -0.19 (-0.26%)
FFL 11.81 Increased By ▲ 0.07 (0.6%)
HUBC 110.00 Increased By ▲ 0.42 (0.38%)
HUMNL 14.10 Increased By ▲ 0.35 (2.55%)
KEL 5.22 Decreased By ▼ -0.09 (-1.69%)
KOSM 7.58 Decreased By ▼ -0.14 (-1.81%)
MLCF 39.00 Increased By ▲ 0.40 (1.04%)
NBP 63.63 Increased By ▲ 0.12 (0.19%)
OGDC 192.70 Decreased By ▼ -1.99 (-1.02%)
PAEL 25.65 Decreased By ▼ -0.06 (-0.23%)
PIBTL 7.29 Decreased By ▼ -0.10 (-1.35%)
PPL 153.00 Decreased By ▼ -2.45 (-1.58%)
PRL 25.50 Decreased By ▼ -0.29 (-1.12%)
PTC 17.44 Decreased By ▼ -0.06 (-0.34%)
SEARL 82.16 Increased By ▲ 3.51 (4.46%)
TELE 7.60 Decreased By ▼ -0.26 (-3.31%)
TOMCL 33.40 Decreased By ▼ -0.33 (-0.98%)
TPLP 8.44 Increased By ▲ 0.04 (0.48%)
TREET 16.32 Increased By ▲ 0.05 (0.31%)
TRG 56.50 Decreased By ▼ -1.72 (-2.95%)
UNITY 27.55 Increased By ▲ 0.06 (0.22%)
WTL 1.36 Decreased By ▼ -0.03 (-2.16%)
BR100 10,495 Increased By 50.1 (0.48%)
BR30 31,049 Decreased By -140.2 (-0.45%)
KSE100 98,165 Increased By 366.4 (0.37%)
KSE30 30,648 Increased By 167.3 (0.55%)

BERLIN: Germany expects to receive 3.8 million doses of Novavax's newly approved COVID-19 vaccine Nuvaxovid by March 20, the health ministry said on Tuesday, as the government looks to persuade unvaccinated Germans to get a shot.

Germany will receive 1.4 million doses in the week of Feb. 21 and should receive the rest of the 3.8 million doses in the subsequent few weeks.

Novavax is expected to deliver 34 million doses to Germany this year. The shipment is a part of the US drugmaker's deal to supply up to 200 million doses to the European Union's 27 member states.

Novavax's protein-based vaccine, which was approved by the European Medicines Agency (EMA) in December, uses alternative technology to the vaccines from Pfizer-BioNTech, , Moderna, AstraZeneca and J&J.

Saudi reports highest daily new COVID-19 infections so far

This could convince reluctant Germans, sceptical about the novel mRNA technology and its long-term effects, to take Novavax's more traditional vaccine and boost Germany's vaccination rate, which is lower than other western European countries.

Data from two large studies showed the vaccine has an efficacy rate of around 90% and the firm said early data showed it was effective in generating an immune response against the more infectious Omicron variant.

Comments

Comments are closed.